Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with ...

Ozempic's expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a gradual loss of kidney function.

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type 2 diabetes and chronic kidney disease, Novo Nordisk said.

诺和诺德（Novo Nordisk）日前宣布，美国FDA已批准其重磅疗法Ozempic（司美格鲁肽，semaglutide），用于降低2型糖尿病合并慢性肾病（CKD）成年患者的肾病恶化、肾功能衰竭（终末期肾病）以及心血管疾病导致的死亡风险。根据新闻稿，此次批准使Ozempic注射剂成为同类药物中适应症范围最广的胰高血糖素样肽-1受体激动剂（GLP-1 RA）。

Efficacy was established based on the time to first occurrence of a primary composite endpoint event, defined as onset of persistent 50% or greater reduction in eGFR according to the Chronic Kidney ...

about a third of adults with diabetes also have chronic kidney disease, according to the US Centers for Disease Control and Prevention The clinical trial tested the efficacy of Ozempic when added ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 ...

Yet another study is supporting the notion that the blockbuster GLP-1 drug Ozempic can help problems drinkers curb their ...